Outcome comparison of pyrotinib with current standard of care in the second/third line setting in advanced non-small cell lung cancer patients with HER2 mutation
Main Authors: | Shiqi Mao, Libo Luo, Shuo Yang, Yan Wang, Fei Zhou, Jia Yu, Bin Chen, Guanghui Gao, Xuefei Li, Chao Zhao, Lei Cheng, Yiwei Liu, Wanying Wang, Keyi Jia, Chuchu Shao, Xinyu Liu, Xiaoxia Chen, Chunxia Su, Caicun Zhou, Fengying Wu, Shengxiang Ren, Xiangxiang Pan, Peifang Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2023-04-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002453 |
Similar Items
-
Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trials
by: Shiqi Mao, et al.
Published: (2023-06-01) -
Efficacy and safety of local ablative therapy for patients with NSCLC and coexisting interstitial lung disease
by: Chuchu Shao, et al.
Published: (2024-04-01) -
Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
by: Yingying Pan, et al.
Published: (2019-04-01) -
P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer
by: Hao Chen, et al.
Published: (2023-09-01) -
Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
by: Li Y, et al.
Published: (2022-12-01)